Melanoma models for the next generation of therapies is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0.816. It has been cited 230 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.816
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →U.S. Department of Defense
Grant: NF170044
U.S. Department of Defense
Grant: CA170628
U.S. Department of Defense
Grant: CA190267
Exelixis
Grant: 62/654,025
Albert Einstein Cancer Center
Grant: 770854
An integrative approach for the exploration of melanoma genetic and immunological interactions
American Cancer Society
Grant: RSG-18-169-01-LIB
Cancer Research UK
Grant: A27412
National Cancer Institute
Grant: R13CA250294
National Cancer Institute
Grant: R01 CA216846
National Cancer Institute
Grant: U01 CA233096
National Cancer Institute
Grant: P50 CA121974
National Cancer Institute
Grant: R01 CA216101
National Cancer Institute
Grant: U01 CA238728
National Cancer Institute
Grant: R01 CA196660
National Cancer Institute
Grant: R01 CA196566
National Cancer Institute
Grant: R01 CA244660
National Cancer Institute
Grant: P30 CA016359
National Cancer Institute
Grant: P01 CA206980
National Cancer Institute
Grant: R01 CA204002
National Cancer Institute
Grant: R01 CA212376
National Cancer Institute
Grant: R01CA237213
National Cancer Institute
Grant: P01 CA128814
Huntsman Cancer Foundation
Grant: K22CA197058
Huntsman Cancer Foundation
Grant: R03CA227349
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: R01 CA182635
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: R01 AR070234
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: P01 CA114046
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: R01 CA253977
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: R01 CA196278
Medical Research Council
Grant: MR/S01473X/1
Identifying the drivers and vulnerabilities of acral lentiginous melanoma through the study of PDX models from Latin American patients
Medical Research Council
Grant: MC_UU_00007/9
Gene-drug interactions in the melanocyte lineage and melanoma
Melanoma Research Alliance
Grant: 687306
European Consortium for Lithium-Sulfur Power for Space Environments
Harry J. Lloyd Charitable Trust
Grant: R01CA240633
KU Leuven
Grant: A22902
KU Leuven
Grant: ERC-ADG-2014 671262
KU Leuven
Grant: C5759/A29061
KU Leuven
Grant: 100282/Z/12/Z
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Grant: R01 CA121118
Pfizer
Grant: 9880150
European Research Council
Grant: 756017
Armoring multifunctional T cells for cancer therapy
NCI NIH HHS
Grant: R01 CA207935
NCI NIH HHS
Grant: R01 CA226888
NIGMS NIH HHS
Grant: R01 GM071725
NCI NIH HHS
Grant: R37 CA240914
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P50 CA217694
European Research Council
Grant: 648489
Chemical Biology in Zebrafish: Drug-Leads and New Targets in the Melanocyte Lineage and Melanoma
European Research Council
Grant: 671262
Elucidating the role of ultraviolet radiation in melanoma
NCI NIH HHS
Grant: R01 CA176839
NCI NIH HHS
Grant: R01 CA232256
NCI NIH HHS
Grant: DP2 CA174499
NCI NIH HHS
Grant: DP2 CA186572
NCI NIH HHS
Grant: P30 CA010815
NCI NIH HHS
Grant: P50 CA225450
NCI NIH HHS
Grant: R01 CA229215
NCI NIH HHS
Grant: R01 CA238317
NIGMS NIH HHS
Grant: R01 GM101171
Cancer Research UK
Grant: 19279
NCI NIH HHS
Grant: P30 CA042014
NCI NIH HHS
Grant: R01 CA103846
NCI NIH HHS
Grant: R01 CA232246
NCI NIH HHS
Grant: R01 CA238163
Cancer Research UK
Grant: 17240
Cancer Research UK
Grant: 22902
NCI NIH HHS
Grant: R01 CA215733
NCI NIH HHS
Grant: R01 CA228216
NCI NIH HHS
Grant: R01 CA238237
NIEHS NIH HHS
Grant: R21 ES032305
NCI NIH HHS
Grant: R35 CA197465
Academy of Medical Sciences
Grant: NAF\R2\180782
NCI NIH HHS
Grant: U54 CA224070
NCI NIH HHS
Grant: P01 CA163222
National Institutes of Health
Grant: 5R01CA253977-03
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
National Institutes of Health
Grant: 1U01CA233096-01A1
Cytokine immunotherapies for melanoma
National Institutes of Health
Grant: 1R01CA238163-01
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
National Institutes of Health
Grant: 5R01CA196660-02
Congenic Mouse Medels of Melanoma for the Characterization of Tumor Immune Responses
European Commission
Grant: 667787
New therapies for uveal melanoma
National Institutes of Health
Grant: 5P01CA128814-08
ER Stress and Mitochondrial Biogenesis in Melanoma
Institut National du Cancer
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5R37CA240914-03
Defining the role of NF1 and SPRED1 loss in melanoma
National Institutes of Health
Grant: 3R01GM071725-13S1
Repression of the hTERT gene during cell differentiation: Administrative Supplement for Equipment
National Institutes of Health
Grant: 5R01CA226888-03
Development of BRAF Dimer Inhibitors to Treat Drug Resistant Melanoma
National Institutes of Health
Grant: 5U01CA238728-04
Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment
Wellcome Trust
Grant: 100282
Developing Personalised Medicine for Malignant Melanoma.
National Institutes of Health
Grant: 5P50CA217694-04
SPORE in Soft Tissue Sarcoma
National Institutes of Health
Grant: 2R01CA216101-06
Mitochondrial Regulation of Antitumor Immunity
National Institutes of Health
Grant: 1DP2CA186572-01
Evolutionary dynamics of melanoma metastasis
National Institutes of Health
Grant: 5R03CA227349-02
An ESC-GEMM platform for rapid melanoma mouse modeling
National Institutes of Health
Grant: 5R35CA197465-04
Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance
National Institutes of Health
Grant: 5R01CA238237-02
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
National Institutes of Health
Grant: 5P30CA010815-28
CONSOLIDATED BASIC CANCER RESEARCH PROGRAM
National Institutes of Health
Grant: 7R01AR070234-03
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
National Institutes of Health
Grant: 5R01CA196566-03
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis
National Institutes of Health
Grant: 5R01CA182635-05
Targeted therapies in mutant BRAF melanoma
National Institutes of Health
Grant: 5R01GM101171-08
Regulation of one carbon metabolism and epigenetics by SIRT5
National Institutes of Health
Grant: 5R01CA121118-14
A High-Throughput Model for Human Melanoma
National Institutes of Health
Grant: 5R01CA238317-02
Lipid programs in melanocyte transformation
National Institutes of Health
Grant: 3P30CA042014-30S2
Cancer Center Support Grant
National Institutes of Health
Grant: 1DP2CA174499-01
An integrative approach to target lineage-specific oncogenic transcription factor
National Institutes of Health
Grant: 1R01CA216846-01
Renalase inhibition for treatment of unresectable melanoma
European Commission
Grant: 731105
EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts
National Institutes of Health
Grant: 5R01CA176839-02
Targeting Oncogenic BRAF And PI3'-Kinase Signaling For Melanoma Therapy
European Commission
Grant: 955575
Training Network for Optimizing Adoptive T cell Therapy of Cancer
National Institutes of Health
Grant: 5R01CA229215-02
Dissecting the complexity of metastasis with mathematical models and quantitative experiments with in zebrafish
National Institutes of Health
Grant: 1R13CA250294-01
MRA Melanoma Models Workshop
National Institutes of Health
Grant: 1K22CA197058-01
BACH2 in Melanoma Development and Resistance
National Institutes of Health
Grant: 2P01CA114046-11A1
Targeted Therapies in Melanoma
National Institutes of Health
Grant: 5R01CA212376-04
An innate immune checkpoint in cancer immunotherapy
National Institutes of Health
Grant: 3R01CA237213-02S1
Diversity Supplement R01CA237213 - Mechanisms of UV-Mediated Melanoma Development
National Institutes of Health
Grant: 2P30CA016359-15
COMPREHENSIVE CANCER CENTER
National Institutes of Health
Grant: 5R01CA204002-05
Inherent tropism and/or immune modulation in melanoma brain metastasis
National Institutes of Health
Grant: 3U54CA224070-04S2
Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA241148)
National Institutes of Health
Grant: 3R01CA215733-02S1
Targeting TERT in Melanoma
National Institutes of Health
Grant: 5R01CA196278-02
Mutant BRAF-regulated transcription factors in melanoma progression
National Institutes of Health
Grant: 1R21ES032305-01
Elucidating epigenetic mechanisms of cellular cadmium toxicity
National Institutes of Health
Grant: 2P50CA121974-06A1
The RAC1 Pathway as aTarget for Melanoma Therapy
National Institutes of Health
Grant: 3P01CA206980-02S2
Genomic Evaluation of the Female Survival Advantages in Melanoma
National Institutes of Health
Grant: 1R01CA228216-01
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
National Institutes of Health
Grant: 5R01CA240633-05
Defining Transcriptional Regulators of Melanoma Initiation using Zebrafish
National Institutes of Health
Grant: 5R01CA103846-15
Cancer biology in the zebrafish
National Institutes of Health
Grant: 7R01CA207935-04
Effect of the aged microenvironment on tumor dormancy
National Institutes of Health
Grant: 5R01CA244660-03
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling
AstraZeneca
Horizon 2020
National Institutes of Health
Pershing Square Foundation
European Commission
Fritz-Bender-Stiftung
Horizon 2020 Framework Programme
“la Caixa” Foundation
Dermatology Foundation
Deutsche Forschungsgemeinschaft
Stichting Tegen Kanker
Wellcome Trust
Army Research Office
Institute of Cancer Research
Fonds Wetenschappelijk Onderzoek
Heritage Foundation
Mark Foundation For Cancer Research
Wellcome Trust
FWCI
15.49
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma
Additional file 1 of Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma
Additional file 1 of Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Additional file 2 of Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Additional file 1 of Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Additional file 2 of Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
Additional file 1 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 1 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 2 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 2 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 3 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 3 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 4 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 4 of Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Additional file 1 of NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma
Additional file 1 of NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma
Additional file 2 of NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma
Additional file 2 of NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma
Additional file 2 of The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
Additional file 2 of The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification